Patient has had surgery within 4 weeks prior to first dose
8. Major surgery within 4 weeks prior to first dose of TAB001 or still recovering from prior surgery;
Major surgery or radiation therapy within 4 weeks prior to the first study dose
Major surgery within 3 weeks prior to first dose
History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery
Major surgery within 3 weeks prior to first dose, prior peripheral stem cell transplant within 12 weeks of study enrollment
Major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks of the first dose of study treatment
Radiation therapy or major surgery within 4 weeks prior to first dose of study agent
No major surgery within 4 weeks of first dose of sEPHB4
History of major surgery within 4 weeks prior to first dose on this study
Major surgery within 4 weeks of first dose of investigational product
Major surgery within 3 weeks prior to first dose
Major surgery within 4 weeks prior to first study dose
Patients with major surgery or radiation therapy within 4 weeks prior to first study dose.
Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
Patient had major surgery within 4 weeks prior to the first dose.
Major surgery within 4 weeks prior to first dose of STA-9090
Major surgery or invasive intervention within 4 weeks prior to first dose
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks prior to first dose
Major surgery within 2 weeks prior to the first dose of lenvatinib.
Surgery within 4 weeks prior to first dose
Major surgery within 2 weeks of the first dose of study treatment
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks prior to first dose.
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 3 weeks prior to first dose
Major surgery within 2 weeks of first dose of lenvatinib
Major surgery within 3 weeks prior to first dose
Major surgery within 3 weeks prior to first dose
Major surgery within 3 weeks prior to first dose
Surgery within 4 weeks prior to first dose
Major surgery within 4 weeks prior to first dose
Surgery within 4 weeks prior to first dose.
Major surgery within 3 weeks prior to first dose
Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medication
Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication
Major surgery or radiation within 4 weeks prior to 1st dose
Major surgery within 4 weeks prior to first dose
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks prior to first dose of ganetespib
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI0680 (AMP-514) or still recovering from prior surgery
Major surgery within four weeks of the first dose of ARQ 092
Major surgery performed within 3 weeks prior to the first dose of study drugs or scheduled for major surgery during the study
Surgery within 4 weeks prior to first dose
Major surgery within 4 weeks prior to first dose of study treatment.
Subjects must not have had major surgery as determined by the PI within 4 weeks before the first dose of investigational agent.
No major surgery within 4 weeks of first dose of SGI-110.
History of major surgery within 4 weeks prior to first dose on this study